SADIE2NCT05972564
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
At risk: Primary completion moved 9 months later.
See at-risk trials from Vanderbilt University Medical Center
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 6 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Sep 30, 2026 to Jun 30, 2027
- Eligibility criteria expanded, about 5 words
- Study completion pushed from Dec 30, 2026 to Dec 30, 2027
- Notable Eligibility criteria expanded, about 23 wordsv7
- Notable Eligibility criteria shortened, about 2 wordsv5
- Notable Eligibility criteria revisedv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Sep 30, 2023 to Sep 6, 2023
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Adipose tissue macrophages
Timeframe: 12 weeks
Flow mediated dilation
Timeframe: 12 weeks
Monocyte chemoattractant protein-1
Timeframe: 12 weeks
Secondary (2)
Pro-inflammatory T cells
IL-6
Arms and interventions
Empagliflozin ArmActive comparator
Empagliflozin is an FDA-approved SGLT2 inhibitor used for the treatment of type 2 diabetes, with off-label use for diabetic kidney disease and for heart failure with reduced ejection fraction even in those without diabetes. To ensure blinding, empagliflozin will be over-encapsulated in identical gelatin capsules as placebo.
Placebo ArmPlacebo comparator
Placebo consists of gelatin capsules.
Drugs: Empagliflozin 25 MG, Placebo
Sites
1 site in 1 country
- Vanderbilt University Medical CenterNashville, Tennessee, United States